Mankind Pharma Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Mankind Pharma (NSE: MANKIND) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 2,050 — against a 52-week high of Rs 2,740 and 1-year return of -18% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 3,400-3,650 Cr, with PAT expectations of Rs 575-630 Cr and margin projections of EBITDA 25-27%. This article covers the Mankind Pharma Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and investor FAQs.

Mankind Pharma Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Why This Quarter Matters

Mankind Pharma enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 determines full-year FY26 performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -18%, this quarter’s results and FY27 guidance will be critical for determining stock trajectory.

Mankind Pharma Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Screen Mankind Pharma fundamentals on Univest Screener.

5 Key Factors That Will Drive Mankind Pharma Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 3,400-3,650 Cr in Q4 FY26 revenue versus Rs 3,186 Cr in Q3. Q4 is seasonally important for the Pharma sector and the ability to convert the pipeline into recognised revenue will be the first performance test.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 25-27% versus EBITDA 25.4% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels.

PAT Quality

Net profit is estimated at Rs 575-630 Cr. Investors will assess whether PAT is driven by operational improvement or non-recurring items. A clean recurring profit print is most positively received by institutional investors.

Management Guidance for FY27

The most consequential output will be FY27 guidance — revenue growth bands, margin targets, and capex plans. Credible FY27 guidance carries significant weight for re-rating potential in the current macro environment.

Dividend Declaration

Mankind Pharma is expected to consider a final dividend of Rs 6-8 per share. The quantum signals management’s confidence in free cash flow generation and sets expectations for FY27 capital allocation.

5 Risks to Watch in Mankind Pharma Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty. For Mankind Pharma, indirect impacts include FII outflows and earnings estimate cuts if global demand slows.

Earnings Miss Risk

If Mankind Pharma’s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus Rs 3,400-3,650 Cr and PAT versus Rs 575-630 Cr as the two primary watchpoints.

FY27 Guidance Below Consensus

If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter currently.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling creates headwinds for Mankind Pharma regardless of fundamentals.

Sector Regulatory Risk

The Pharma sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Mankind Pharma’s profitability.

Mankind Pharma Share Price and Analyst Ratings

Mankind Pharma is trading at Rs 2,050 as of early April 2026, against a 52-week high of Rs 2,740 and 52-week low of Rs 1,820. Market cap stands at Rs 82,400 Cr.

Download the Univest iOS App or Univest Android App to track Mankind Pharma live and receive real-time Q4 result alerts.

Conclusion

Mankind Pharma Q4 FY26 results on May 2026 (Expected) will be a key event for Pharma sector investors. Analysts project PAT of Rs 575-630 Cr and revenue of Rs 3,400-3,650 Cr. At Rs 2,050 with analyst targets from Rs 2,500 to Rs 2,600, FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews, visit Univest Blogs.

Frequently Asked Questions

What is the Mankind Pharma Q4 results 2026 date?

The Mankind Pharma Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a final dividend recommendation.

What is the Mankind Pharma Q4 FY26 PAT estimate?

Analysts estimate Mankind Pharma Q4 FY26 PAT at Rs 575-630 Cr, based on revenue of Rs 3,400-3,650 Cr and margin of EBITDA 25-27%.

What is Mankind Pharma’s share price ahead of Q4 results?

Mankind Pharma is trading at Rs 2,050. The 52-week high is Rs 2,740 and low is Rs 1,820. The 1-year return is -18% and market cap is Rs 82,400 Cr.

Will Mankind Pharma declare a dividend in Q4 FY26?

Mankind Pharma is expected to consider a final dividend of Rs 6-8 per share at the Q4 FY26 board meeting on May 2026 (Expected).

Which analysts have a Buy rating on Mankind Pharma?

MOFSL (Buy, Rs 2,600), YES Securities (Buy, Rs 2,550), JM Financial (Add, Rs 2,450), Bernstein (Outperform, Rs 2,500) have positive ratings heading into Q4 FY26.

What were Mankind Pharma Q3 FY26 results?

Mankind Pharma reported Q3 FY26 revenue of Rs 3,186 Cr and PAT of Rs 542 Cr, with margin at EBITDA 25.4%.

When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read both previews on Univest Blogs.

Is Mankind Pharma a good investment ahead of Q4 results?

This depends on your risk appetite. Mankind Pharma has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before investing.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only. All financial data and analyst estimates are sourced from publicly available information. Verify before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

UPL Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Zee Entertainment Enterprises Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Sun TV Network Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Sapphire Foods India Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Metro Brands Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook